Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Feature|Articles|September 14, 2026
Why Fragmented Contract Processes Are Slowing Pharmaceutical Operations
Author(s)Tom Cowen
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
Advertisement
Advertisement
The pharmaceutical industry has made significant investments in digital transformation, ranging from AI-led drug discovery and clinical trial optimization to advanced analytics and real-world evidence generation. As a result, digital technologies are changing how the industry discovers, commercializes and delivers medicines.
Related to this article
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the evidence shows.
Dr. Jay Lalezari, CEO and CMO of CytoDyn, discusses how Leronlimab’s unique CCR5-blocking mechanism has carried it from HIV, to Covid-19, to a promising, one-of-a-kind proof of concept in colorectal cancer.
FDA grants accelerated approval to INOVIO’s Voceryq for reducing surgery frequency in adults with recurrent respiratory papillomatosis.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Advertisement
Advertisement